We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+9.5%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$168M
AUM Growth
-$12M
Cap. Flow
-$14M
Cap. Flow %
-8.32%
Top 10 Hldgs %
55.87%
Holding
32
New
10
Increased
1
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$9.44M
2
LEGN icon
Legend Biotech
LEGN
+$9M
3
ALMS
Alumis Inc
ALMS
+$8.23M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$7.84M
5
CATX icon
Perspective Therapeutics
CATX
+$5.73M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$11.9M
2
BPMC
Blueprint Medicines
BPMC
+$8.54M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$6.51M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$6.33M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$6.24M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$11.7M 6.96%
286,162
-50,324
-15% -$2.13M
SRPT icon
2
Sarepta Therapeutics
SRPT
$1.82B
$11.6M 6.92%
+73,500
New +$9.44M
GERN icon
3
Geron
GERN
$924M
$11.6M 6.91%
2,736,663
-23,834
-0.9% -$92.9K
MRUS
4
DELISTED
Merus
MRUS
$10.3M 6.16%
174,844
-81,084
-32% -$3.93M
INSM icon
5
Insmed
INSM
$23.5B
$8.64M 5.15%
129,000
-121,000
-48% -$4.69M
LEGN icon
6
Legend Biotech
LEGN
$4.31B
$8.64M 5.15%
+195,000
New +$9M
ALMS
7
Alumis Inc
ALMS
$3.65B
$8.23M 4.9%
+618,750
New +$8.23M
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$8.15M 4.86%
75,638
-85,312
-53% -$8.54M
IRON icon
9
Disc Medicine
IRON
$2.91B
$7.5M 4.47%
+166,500
New +$5.66M
DAWN
10
DELISTED
Day One Biopharmaceuticals
DAWN
$7.39M 4.4%
+536,095
New +$7.84M
DFTX
11
Definium Therapeutics
DFTX
$5.88B
$6.96M 4.15%
965,426
-36,026
-4% -$315K
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.6B
$6.6M 3.93%
169,369
-140,000
-45% -$5.6M
PRAX icon
13
Praxis Precision Medicines
PRAX
$8.77B
$6.34M 3.78%
153,379
-6,107
-4% -$289K
KURA icon
14
Kura Oncology
KURA
$964M
$6.32M 3.76%
306,762
-58,282
-16% -$1.2M
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
$6.05M 3.6%
430,245
-116,791
-21% -$1.9M
LBPH
16
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$5.92M 3.53%
218,981
-51,578
-19% -$1.02M
CGON icon
17
CG Oncology
CGON
$6.34B
$5.52M 3.29%
174,876
-145,502
-45% -$5.04M
JSPR icon
18
Jasper Therapeutics
JSPR
$29.4M
$4.96M 2.96%
218,614
-71,329
-25% -$1.71M
TRVI icon
19
Trevi Therapeutics
TRVI
$2.71B
$4.4M 2.62%
+1,474,926
New +$4.1M
TYRA icon
20
Tyra Biosciences
TYRA
$1.91B
$4.23M 2.52%
+264,660
New +$4.56M
CATX icon
21
Perspective Therapeutics
CATX
$341M
$3.95M 2.35%
+396,242
New +$5.73M
BDTX icon
22
Black Diamond Therapeutics
BDTX
$103M
$3.89M 2.32%
+835,000
New +$4.48M
CNTX icon
23
Context Therapeutics
CNTX
$55.1M
$3.78M 2.25%
1,886,232
+1,160,281
+160% +$2M
CLYM
24
Climb Bio
CLYM
$727M
$3.56M 2.12%
+500,000
New +$3.33M
PMN icon
25
ProMIS Neurosciences
PMN
$136M
$1.59M 0.95%
42,383
– –
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q2 2024 Portfolio in Review

As of Q2 2024, Ally Bridge Group held 32 positions worth $168M, down 6.7% from $180M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Ally Bridge Group withdrew a net $14M in Q2 2024, closing 7 positions and reducing 13 holdings. Its most notable exit was Verona Pharma, an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Ally Bridge Group opened a new position in Sarepta Therapeutics worth $11.6M.

  • Ally Bridge Group's largest Q2 2024 buy was Sarepta Therapeutics: 73,500 shares worth $11.6M.
  • Ally Bridge Group added most to Context Therapeutics in Q2 2024, an estimated $2M increase.
  • Ally Bridge Group's biggest Q2 2024 reduction was Blueprint Medicines, cutting an estimated $8.54M.
  • Ally Bridge Group fully exited Verona Pharma in Q2 2024, selling an estimated $11.9M.
  • Ally Bridge Group's ten largest holdings make up 56% of its $168M portfolio in Q2 2024.
  • Ally Bridge Group opened 10 new positions and closed 7 in Q2 2024.
  • Ally Bridge Group's portfolio value fell 6.7% quarter-over-quarter to $168M.

Based on Ally Bridge Group's 13F filing for Q2 2024, filed 14 Aug 2024.